Internet Explorer 11 is not supported

For optimal browsing, we recommend Chrome, Firefox or Safari browsers.

FDA Approves Harvoni, Another Expensive Hepatitis C Drug

Demand for the treatment is likely to surge in Medicaid because the drug reduces side effects and requires fewer office visits, presenting a problem for state budgets.

The Food and Drug Administration has approved yet another expensive but highly effective hepatitis C medication, which Medicaid experts and insurers warn could ignite demand because it’s easier to take and comes with fewer side effects than other medications used to treat the disease.

Harvoni is now the first once-daily medication that can cure hepatitis C in as few as eight weeks without injections or other pills that can cause flu-like symptoms, anxiety and a host of other side effects. It comes from California-based Gilead Sciences, which introduced the hepatitis C drug Sovaldi in late 2013 at a cost of about $84,000 for a 12-week regiment. When paired with other drugs (that can induce painful side effects), Sovaldi showed a cure rate of more than 90 percent in FDA trials, but its high price tag sparked Congressional inquiries and moral dilemmas for states, which shoulder much of the burden for hepatitis C treatment through their Medicaid programs.

“By providing very high cure rates in as little as eight weeks and completely eliminating the need for interferon and ribavirin, which are challenging to take and tolerate, Harvoni significantly advances treatment for patients with the most common form of hepatitis C in the United States,” said Nezam Afdhal, the director of Hepatology at Beth Israel Deaconess Medical Center and a main investigator in the FDA’s clinical trials, in a statement.

Harvoni also boasted a clinical success rate of 94 to 99 percent in FDA trials. 

Hepatitis C is a viral infection that eventually leads to liver failure, cancer or other life-threatening health problems. In the developed world, it’s most commonly spread through intravenous drug use. Many of the estimated 3.2 million people living with hepatitis C in the United States are poor, imprisoned or elderly, which means the cost of care falls disproportionately on Medicaid and Medicare. One analysis put the potential cost of Sovaldi to states at $55 billion if they covered their entire hepatitis C populations.

The pricing for Harvoni is different, though. About 40 percent of patients, those with less advanced cases, could take the drug for eight weeks at a cost of $63,000. More typically, patients will take a 12-week supply at $94,500, according to the company. High-cost, specialty drugs are a rapidly growing market -- and a growing issue for states.

When Govering last reported on Sovaldi, about half of the states were requiring “prior authorization” for the use of Sovaldi, essentially creating lists of criteria that patients must meet before a doctor can prescribe the drug. Those criteria commonly require that patients be in the worst stage of hepatitis C, which is cirrhosis, and that they be drug-free for a period of time. 

Today, some 37 states require prior authorization, according to a report commissioned by the Medicaid Health Plans of America, a trade group representing insurers that contract with states to manage their Medicaid programs. That report details some of the more severe requirements from state Medicaid agencies, such as a rule in Alaska requiring people with hepatitis C to be drug-and-alcohol free for a minimum of three years before getting Sovaldi. 

“It has grown and it has grown substantially, because even in the state where there is no decision or they don’t have a Medicaid [preferred-drug list], we know they’re considering moving in that direction,” said Jeff Myers, the group’s CEO.

But the issue for state budget makers is a likely uptick in demand, says Myers and Matt Salo, who heads the National Association of Medicaid Directors. Many patients and doctors were aware of Harvoni’s potential when Sovaldi was released, and many decided to wait for it because it reduces side effects and doesn’t require repeated office visits for the therapies that accompany other hepatitis C treatments, Salo said.

“We’ve known that the first nine months of the availability of the hepatitis C cure was not the thing that was going to get 3 million people treated,” he said.

Many of those doctors will encourage their patients to take the opportunity presented by Harvoni -- rightly so, Salo said. But there’s still an undeniable problem for state budgets, even if the costly drug prevents things like liver transplants later on, because those costs will surge in the near term.

“No physician is going to want to say to a patient, ‘No, go without it’ [because the state faces a budget situation],” Salo said. “That’s not their job.”

Chris covers health care for GOVERNING. An Ohio native with an interest in education, he set out for New Orleans with Teach For America after finishing a degree at Ohio University’s E.W. Scripps School of Journalism. He later covered government and politics at the Savannah Morning News and its South Carolina paper. He most recently covered North Carolina’s 2013 legislative session for the Associated Press.
Special Projects
Sponsored Stories
Sponsored
Workplace safety is in the spotlight as government leaders adapt to a prolonged pandemic.
Sponsored
While government employees, students and the general public had to wait in line for hours in the beginning of the pandemic, at-home test kits make it easy to diagnose for the novel coronavirus in less than 30 minutes.
Sponsored
Governments around the nation are working to design the best vaccine policies that keep both their employees and their residents safe. Although the latest data shows a variety of polarizing perspectives, there are clear emerging best practices that leading governments are following to put trust first: creating policies that are flexible and provide a range of options, and being in tune with the needs and sentiments of their employees so that they are able to be dynamic and accommodate the rapidly changing situation.
Sponsored
Service delivery and the individual experience within health and human services (HHS) is often very siloed and fragmented.
Sponsored
In this episode, Marianne Steger explains why health care for Pre-Medicare retirees and active employees just got easier.
Sponsored
Government organizations around the world are experiencing the consequences of plagiarism firsthand. A simple mistake can lead to loss of reputation, loss of trust and even lawsuits. It’s important to avoid plagiarism at all costs, and government organizations are held to a particularly high standard. Fortunately, technological solutions such as iThenticate allow government organizations to avoid instances of text plagiarism in an efficient manner.
Sponsored
Creating meaningful citizen experiences in a post-COVID world requires embracing digital initiatives like secure and ethical data sharing, artificial intelligence and more.
Sponsored
GHD identified four themes critical for municipalities to address to reach net-zero by 2050. Will you be ready?
Sponsored
As more state and local jurisdictions have placed a priority on creating sustainable and resilient communities, many have set strong targets to reduce the energy use and greenhouse gases (GHGs) associated with commercial and residential buildings.